Opinion: A truce in the stem cell wars?
By Richard Hayes,
San Francisco Examiner
| 11. 24. 2006
The contentious midterm elections clearly left a mark on the politics of stem cell research, but it’s not clear what the mark signifies. Missouri’s closely watched stem cell initiative barely squeaked by with 51 per cent of the vote, despite a $30 million campaign financed almost entirely by a single wealthy couple. And in nine congressional races identified as high priority by stem cell research advocates, the stem cell candidate won in only four.
At the same time, at least 60 percent of all races in which stem cell research was an issue — including high-profile races for Congress, the Senate, and governorships — were won by the candidate supporting the research. And there’s no denying the frenzied TV and YouTube campaigning by partisans on all sides reinforced the identity of "stem cells" as an iconic trope of the culture wars.
Incoming Democratic House Speaker Nancy Pelosi has pledged a vote on federal stem cell funding "within the first 100 hours" of the new Congress. It appears there are now enough votes in the Senate to override a presidential veto...
Related Articles
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Billy Perrigo, TIME | 03.11.2024
The U.S. government must move “quickly and decisively” to avert substantial national security risks stemming from artificial intelligence (AI) which could, in the worst case, cause an “extinction-level threat to the human species,” says a report commissioned by the U.S...
By Gerry Smith, Bloomberg | 03.12.2024
When Celenise Mahmood first learned about two new gene therapies that could cure sickle cell disease, she felt a wave of relief.
Her 9-year-old son, Navid, has the inherited blood disorder. By age 5, he’d had over 30 life-saving blood...